The FDA has scuttled Merus’ plans to win a speedy approval for i | The FDA has scuttled Merus’ plans to win a speedy approval ...

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...

The U.S. Food and Drug Administration on Tuesday extended the review of Merus' gene-targeting cancer therapy to allow sufficient time to assess some recent information submitted by the company, ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Merus on Tuesday said the Food and Drug Administration extended its review of the clinical-stage oncology company's proposed zenocutuzumab cancer treatment.

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...

Reports Q3 revenue $11.8M, consensus $7.83M. “I’m encouraged by our continued operational effectiveness, with phase 3 trials accelerating for ...

Third Quarter 2024 Results Key Financial Results Revenue: US$11.8m (up 6.7% from 3Q 2023).